Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Oncology and Pemetrexed, with related work in Patient satisfaction, Ubiquitin, Trastuzumab. Notable publications include 'Consensus for HER2 alterations testing in non-small-cell lung cancer', 'LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer...', and 'Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized...'.
Serous and Exosomal LDH-C4 as a Potential Diagnostic and Prognostic Biomarker of Cervical Carcinoma.
[Biomechanical study on wing shaped titanium plate fixation of acetabular anterior column and posterior hemi-transverse fracture under multiple working conditions].
Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)
The influence of hospital services on patient satisfaction in OPDs: evidence from the transition to a digital system in South Punjab, Pakistan
P53 upregulation by USP7-engaging molecular glues
Consensus for HER2 alterations testing in non-small-cell lung cancer
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy
MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
MA02.06 A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC
First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE)